David Murdock, MD
Cardiovascular Disease · Wausau, WINPI 1942200910
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $137,293 of the $163,897 with a category attached, or 83.8%. 20 manufacturers reported payments, led by Boehringer Ingelheim at 56.9% of the total. Reporting peaked in 2019 at $64,005 and has fallen 98.9% since, to $683 in 2024. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $787.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$93K
- Lilly USA, LLC$42K
- Regeneron$10K
- Novartis$8K
- Amgen$6K
- Esperion Therapeutics, Inc.$2K
- plus $2K from 14 others
Across 47 payments — averaging $25,551 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$863K
- Amgen$297K
- Boehringer Ingelheim$17K
- Amryt Pharma Holdings Ltd$16K
- E.r. Squibb & Sons, L.L.C.$5K
- Chiesi USA, Inc.$1K
- plus $1K from 2 others
What the payments were for
- Consulting fees$14,6409%
- Speaking & faculty fees$137,29384%
- Travel & lodging$6,0964%
- Food & beverage$5,6973%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 89 | $93,182 |
| Lilly USA, LLC | 37 | $42,461 |
| Regeneron | 14 | $10,399 |
| Novartis | 12 | $7,513 |
| Amgen | 16 | $6,343 |
| Esperion Therapeutics, Inc. | 1 | $1,500 |
| Novo Nordisk | 14 | $380 |
| AstraZeneca | 5 | $351 |
| Bayer | 3 | $250 |
| Pfizer | 2 | $227 |
| Johnson & Johnson | 4 | $208 |
| Regeneron Healthcare Solutions, Inc. | 2 | $204 |
| Medtronic | 1 | $180 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| United Therapeutics Corporation | 1 | $125 |
| Abbott | 1 | $116 |
| Inari Medical, Inc. | 1 | $98 |
| Boston Scientific | 1 | $89 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $80 |
| Janssen Scientific Affairs, LLC | 1 | $67 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$163,897 in reported general payments places this provider in the 95th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Wausau
- Bryan AustinWausau$6K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- Imdad AhmedJanesville$164K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Tadeo Diaz BalderramaFond du Lac$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.